AKT1 and Bloom syndrome: To contextualize this finding, Figure 6H also shows that inhibiting AKT1 with AZD5363 leads to a decrease in viability in the presence of BLM by approximately 4%, which is comparable to that of suppressing SGK1 using siRNA.